Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Randomized Double Blind Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients With Acute Myocardial Infarction

Next Previous
Search
Trial Profile

A Prospective Randomized Double Blind Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients With Acute Myocardial Infarction

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NBS 10 (Primary)
  • Indications Myocardial infarction
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PreSERVE-AMI
  • Sponsors Amorcyte; Caladrius Biosciences

    • Most Recent Events

    • 26 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 15 Mar 2016 According to a Caladrius Biosciences media release, the company announced the decision to conclude the study after two year rather than three year follow-up as the important data has been realized and to avoid additional material expenses.
    • 02 Jun 2015 Results published in the American College of Cardiology 64th Annual Scientific Session and Expo, as per NeoStem media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top